News

Immutep Reports First Results from INSIGHT-004 Study

1 June 2020 First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCO Encouraging early activity signals in a variety of cancer indications Overall, 33% of patients showed…

Immutep Announces Improving Data from Phase II TACTI-002 Study

1 June 2020 First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC) Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR) Progression free survival (PFS) continues to improve in…

Immutep Receives A$3.6 Million R&D Tax Incentive from French Government

29 May 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €2,173,454 (~ A$3,630,000) research and development (R&D) tax incentive payment in cash…

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

26 May 2020 Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion…

Australia’s top scientists elected as Fellows of the Academy

25 May 2020 An Australian scientist who identified the cause of mass frog extinctions across the globe is among a group of scientists being acknowledged today for their outstanding contributions to science. Associate Professor Lee Berger’s research into…

Matchmaking platform to boost local manufacturing supply chains

19 May 2020 Via the Hon Karen Andrews MP, Minister for Health Australian businesses wanting to play their part in the response to the COVID-19 pandemic will have greater access to potential partners and customers thanks to an…

Cloud-based bioinformatics platform fast-tracking genomic analysis

21 May 2020 Researchers at the University of Melbourne Centre for Cancer Research (UMCCR) have established a reliable, scalable and fast bioinformatics platform to analyse the genomic data of hundreds of cancer patients. This new cloud-computing based platform…

COVID-19 prevention trial opens for high risk healthcare workers

20 May 2020 The first gold standard Australian clinical trial to determine whether the drug hydroxychloroquine can prevent COVID-19 is now open. The study, called COVID SHIELD, will recruit frontline and allied health care professionals, aiming to reduce…

$400 million funding boost for health and medical research

20 May 2020 The Morrison Government will invest almost $400 million in world-leading health and medical research projects to improve the lives of all Australians. Our Government will strengthen Australians’ health through research to prevent illness and deliver…

VivaZome and Cytiva enter into an agreement on downstream technology for exosome purification

21 May 2020 VivaZome Therapeutics Pty Ltd (“VivaZome”) and Cytiva, formerly part of GE Healthcare Life Sciences, have entered into an agreement where Cytiva’s range of purification technologies, including Fibro, will be applied to VivaZome’s selected exosome fractions,…

Israel becomes first Middle Eastern market for Sienna’s hTERT IVD

21 May 2020 Sienna Cancer Diagnostics Ltd is pleased to announce the appointment of Zotal Ltd (“Zotal”) as its exclusive distributor in Israel. The distribution agreement provides Zotal with the right to sell Sienna’s hTERT IVD to pathology…

MCRI launches landmark study into children’s COVID-19 immune responses with assistance from Rio Tinto

19 May 2020 The Murdoch Children’s Research Institute (MCRI) has launched its COVID Immune research program to investigate COVID-19 effects on children’s immune systems. The new program, an Australian first, has been made possible with support from Rio Tinto,…

Home

News & opinion

Member Directory

Events